Exploring minimally invasive approach to define stages of type 1 diabetes remotely
Kontola, Helena; Alanko, Inka; Koskenniemi, Jaakko J; Löyttyniemi, Eliisa; Itoshima, Saori; Knip, Mikael; Veijola, Riitta; Toppari, Jorma; Kero, Jukka (2022-08-24)
Helena Kontola, Inka Alanko, Jaakko J. Koskenniemi, Eliisa Löyttyniemi, Saori Itoshima, Mikael Knip, Riitta Veijola, Jorma Toppari, and Jukka Kero. Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely. Diabetes Technology & Therapeutics.Sep 2022.655-665.http://doi.org/10.1089/dia.2021.0554
© 2022, Mary Ann Liebert, Inc., publishers. This is the accepted version of the following article: Helena Kontola, Inka Alanko, Jaakko J. Koskenniemi, Eliisa Löyttyniemi, Saori Itoshima, Mikael Knip, Riitta Veijola, Jorma Toppari, and Jukka Kero. Exploring Minimally Invasive Approach to Define Stages of Type 1 Diabetes Remotely. Diabetes Technology & Therapeutics.Sep 2022.655-665, which has now been formally published in final form at Diabetes Technology & Therapeutics at http://doi.org/10.1089/dia.2021.0554. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.
https://rightsstatements.org/vocab/InC/1.0/
https://urn.fi/URN:NBN:fi-fe2023031431492
Tiivistelmä
Abstract
Objectives: New methods are pivotal in accurately predicting, monitoring, and diagnosing the clinical manifestation of type 1 diabetes (T1D) in high-risk children. Continuous glucose monitoring (CGM) is a valuable tool for patients with T1D, but there is still a knowledge gap regarding its utility in the prediction of diabetes. The current study explored whether 10-day CGM or CGM during an oral glucose tolerance test (OGTT) performed in the laboratory or at home (home-OGTT) could be accurate in detecting stages of T1D.
Research Design and Method: Forty-six subjects 4–25 years of age carrying genetic risk for T1D were recruited and classified into the following groups: islet autoantibody (IAb) negative, one IAb, and stages 1–3 of T1D, based on the laboratory OGTT and IAb results at baseline. A 10-day CGM was initiated before the OGTT.
Results: In this study, we showed that CGM was sensitive in detecting asymptomatic individuals at stage 3, and dysglycemic individuals in stage 2 of T1D both during OGTT and the 10-day period. CGM also showed significant differences in several variables during the 10-day sensoring among individuals at different stages of T1D. Furthermore, CGM showed different OGTT profiles and detected significantly more abnormal OGTT results when compared with plasma glucose.
Conclusions: CGM together with home-OGTT could detect stages of T1D and offer an alternative method to confirm normoglycemia in high-risk individuals.
Kokoelmat
- Avoin saatavuus [31657]